ATG7 and myeloid sarcoma: GRN, ATG7, and LC3-II are all elevated in patients with metabolic syndrome (MS), which are a family of diseases linked to dysfunctional metabolic processes leading to both fat accumulation and insulin insensitivity (Li et al., 2014; Rochlani et al., 2017; Regufe et al., 2020).